Summary
Manual facemask ventilation, a core component of elective and emergency airway management, is classified as an aerosol generating procedure. This designation is based on a single epidemiological study suggesting an association between facemask ventilation and transmission from the SARS 2003 outbreak. There is no direct evidence to indicate whether facemask ventilation is a high-risk procedure for aerosol generation. We conducted aerosol monitoring during routine facemask ventilation, and facemask ventilation with an intentionally generated leak, in anaesthetised patients with neuromuscular blockade. Recordings were made in ultraclean theatres and compared against the aerosol generated by the patient’s own tidal breathing and coughs. Respiratory aerosol from tidal breathing was reliably detected above the very low background particle concentrations (191 (77-486 [3.8-1313]) versus 2.1 (0.7-4.6 [0-12.9] particles.l-1 median(IQR)[range], n=11, p=0.002). The average aerosol concentration detected during facemask ventilation both without a leak (3.0 particles.l-1 (0 – 9 [0-43])) and with an intentional leak (11 particles.l-1 (7.0 – 26 [1-62])) was 64-fold and 17-fold lower than that of tidal breathing (p=0.001 and p=0.002 respectively). The peak particle concentration during facemask ventilation both without a leak (60 particles.l-1 (0 – 60 [0-120])) and with a leak (120 particles.l-1 (60 – 180 [60-480]) were respectively 20-fold and 10-fold lower than a cough (1260 particles (800 – 3242 [100-3682]), p=0.002 and p=0.001 respectively). This study demonstrates that facemask ventilation, even performed with an intentional leak, does not generate high levels of bioaerosol. On the basis of this evidence, facemask ventilation should not be considered an aerosol generating procedure.
Competing Interest Statement
AEP declares advisory board work for Lateral Pharma and consultancy for and research grants from Eli Lilly for projects unrelated to this study. Forbes McGain is a co-inventor (and associated patent holder) of a portable isolation hood designed to reduce aerosol exposure from respiratory infections.
Funding Statement
The AERATOR study is registered in the ISRCTN registry (ISRCT:N21447815). Andrew Shrimpton is an NIHR funded doctoral Research Fellow, NIHR301520. Bryan Bzdek is supported by the Natural Environment Research Council (NE/P018459/1). Fergus Hamilton is a Wellcome GW4 funded Clinical Doctoral Fellow. AERATOR is funded by an NIHR-UKRI rapid rolling grant (Ref: COV0333).
This report presents independent research commissioned by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, UKRI, or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by the Greater Manchester REC committee (Reference: 20/NW/0393) as part of the AERATOR study (approved 18/09/2020). The study was granted Urgent Public Health status by NIHR and is registered in the ISRCTN registry (ISRCT:N21447815).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵Aerosolisation and transmission of SARS-CoV-2 in healthcare settings (AERATOR) study group - Carrie White, James Murray, Johannes Keller, Jules Brown, Andrew Shrimpton, Anthony Pickering, Timothy Cook, Mark Gormley, David Arnold, George Nava, Jonathan Reid, Bryan R Bzdek, Sadiyah Sheikh, Florence Gregson, Fergus Hamilton, Nick Maskell, James Dodd, Ed Moran
Data Availability
Data available on request from the authors
